Table 2.
Parameter | n | Empa baseline | Empa 12 weeks | Change | p-value | n | Placebo baseline | Placebo 12 weeks | Change | p-value |
---|---|---|---|---|---|---|---|---|---|---|
Brachial systolic BP (mmHg) | 30 | 131.4 ± 18.2 | 124.1 ± 12.9 | − 6.8 ± 10.9 | 0.005 | 16 | 130.3 ± 22.0 | 129.2 ± 16.6 | − 1.1 ± 16.5 | 0.796 |
Brachial diastolic BP (mmHg) | 30 | 75.4 ± 10.1 | 73.3 ± 9.0 | − 1.9 ± 7.9 | 0.269 | 16 | 76.0 ± 12.6 | 75.3 ± 8.7 | − 0.7 ± 9.5 | 0.877 |
Brachial heart rate (bpm) | 30 | 63.1 ± 10.2 | 63.3 ± 13.7 | − 0.5 ± 8.3 | 0.650 | 16 | 60.0 ± 9.3 | 58.1 ± 12.6 | − 1.9 ± 8.0 | 0.201 |
Systolic 24 h ABP (mmHg) | 33 | 120.8 ± 16.2 | 117.5 ± 12.0 | − 4.3 ± 11.6 | 0.038 | 14 | 122.1 ± 15.1 | 128.3 ± 18.1 | + 4.7 ± 8.6 | 0.084 |
Diastolic 24 h ABP (mmHg) | 33 | 72.2 ± 9.4 | 70.9 ± 7.6 | − 2.2 ± 7.3 | 0.085 | 14 | 74.6 ± 10.1 | 77.5 ± 10.6 | + 1.3 ± 3.8 | 0.246 |
Central systolic BP (mmHg) | 30 | 119.1 ± 15.2 | 112.7 ± 10.5 | − 5.9 ± 9.1 | 0.008 | 16 | 118.2 ± 18.7 | 117.0 ± 14.4 | − 1.2 ± 13.4 | 0.877 |
Central pulse pressure (mmHg) | 30 | 42.7 ± 9.1 | 38.5 ± 7.7 | − 4.0 ± 4.5 | < 0.001 | 16 | 41.1 ± 9.0 | 40.8 ± 8.9 | − 0.4 ± 8.0 | 0.776 |
Forward pulse pressure height (mmHg) | 30 | 28.8 ± 6.3 | 26.2 ± 5.5 | − 2.4 ± 3.8 | 0.001 | 16 | 27.9 ± 7.3 | 27.6 ± 7.6 | − 0.3 ± 6.2 | 0.856 |
Resting pulse pressure height (mmHg) | 30 | 17.8 ± 3.9 | 15.8 ± 3.5 | − 1.9 ± 2.3 | < 0.001 | 16 | 17.2 ± 3.8 | 16.3 ± 4.5 | + 3.7 ± 1.0 | 0.182 |
Data are given as mean ± standard deviation
ABP ambulatory blood pressure, BP blood pressure, Empa empagliflozin